Skip to main content
. 2019 Feb;31(1):152–161. doi: 10.21147/j.issn.1000-9604.2019.01.10

1.

Demographic and baseline clinical characteristics of patients with N-DLBCL and EN-DLBCL

Characteristics n (%) P
All patients N-DLBCL EN-DLBCL
Total 1,085 679 (62.6) 406 (37.4)
Gender 0.751
 Male 608 (56.0) 383 (56.4) 225 (55.4)
 Female 477 (44.0) 296 (43.6) 181 (44.6)
Age (year) 0.035
 ≤60 716 (66.0) 464 (68.3) 252 (62.1)
 >60 369 (34.0) 215 (31.7) 154 (37.9)
Number of extranodal sites 0.002
 0 or 1 837 (77.1) 545 (80.3) 292 (71.9)
 ≥2 248 (22.9) 134 (19.7) 114 (28.1)
Ann Arbor stage <0.001
 I 268 (24.7) 125 (18.4) 143 (35.2)
 II 435 (40.1) 293 (43.2) 142 (35.0)
 III 166 (15.3) 139 (20.5) 27 (6.7)
 IV 216 (19.9) 122 (18.0) 94 (23.1)
B symptoms 0.021
 Presence 204 (18.8) 142 (20.9) 62 (15.3)
 Absence 881 (81.2) 537 (79.1) 344 (84.7)
Bone marrow involvement 0.012
 Presence 79 (7.3) 39 (5.7) 40 (9.9)
 Absence 1,006 (92.7) 640 (94.3) 366 (90.1)
Bulky disease <0.001
 Presence 100 (9.2) 83 (12.2) 17 (4.2)
 Absence 985 (90.8) 596 (87.8) 389 (95.8)
ECOG performance status 0.129
 0 or 1 883 (81.4) 562 (82.8) 321 (79.1)
 ≥2 202 (18.6) 117 (17.2) 85 (20.9)
Pathological classification 0.062
 GCB 302 (27.8) 185 (27.2) 117 (28.8)
 Non-GCB 765 (70.5) 478 (70.4) 287 (70.7)
 Other 18 (1.7) 16 (2.4) 2 (0.5)
Ki-67 index (%) 0.027
 ≤90 857 (79.0) 552 (81.3) 305 (75.1)
 >90 194 (17.9) 105 (15.5) 89 (21.9)
 Unknown 34 (3.1) 22 (3.2) 12 (3.0)
LDH 0.001
 Normal 595 (54.8) 345 (50.8) 250 (61.6)
 1−2 fold 365 (33.6) 242 (35.6) 123 (30.3)
 >2 fold 125 (11.5) 92 (13.5) 33 (8.1)
IPI score 0.157
 0 268 (24.7) 158 (23.3) 110 (27.1)
Table 1 (continued)